Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Xinan ShengXieqiao YanLin WangYanxia ShiXin YaoHong LuoBenkang ShiZhenhua LiuZhisong HeGuohua YuJianming YingWeiqing HanChanglu HuYun LingZhihong ChiChuanliang CuiLu SiJianmin FangAiping ZhouJun GuoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
RC48-ADC demonstrated a promising efficacy with a manageable safety profile in patients with HER2+ locally advanced or mUC who had failed at least one line of systemic chemotherapy.
Keyphrases
- locally advanced
- phase ii study
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- diffusion weighted imaging
- open label
- diffusion weighted
- radiation therapy
- cancer therapy
- small cell lung cancer
- contrast enhanced
- clinical trial
- cross sectional
- magnetic resonance imaging
- double blind
- computed tomography
- placebo controlled